Board Meeting
Fabino Enterprises Reschedules Board Meeting
Fabino Enterprises rescheduled its board meeting to November 12, 2026, to approve unaudited standalone and consolidated results for the half year ended September 30, 2026.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.


Bearish
7
Neutral
3
Bullish
4
Bearish
7
Neutral
19
Bullish
20
Bearish
0
Neutral
16
Bullish
16
Bearish
0
Neutral
16
Bullish
16
Bearish
0
Neutral
16
Bullish
16
Bearish
0
Neutral
16
Bullish
16
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q2 FY26
Board Meeting
Fabino Enterprises rescheduled its board meeting to November 12, 2026, to approve unaudited standalone and consolidated results for the half year ended September 30, 2026.
Board Meeting
Fabino Enterprises will hold a Board meeting on November 11, 2026, to approve unaudited standalone financial results for the half year ended September 30, 2026.
Fabino Enterprises Ltd (FABINO) is currently trading at 20.31 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Fabino Enterprises Limited is a small, publicly listed Indian pharmaceuticals and FMCG company that manufactures, packs and markets over 70 products across allopathic, herbal and consumer wellness categories under its own brands, operates a manufacturing/processing centre at Sonipat Haryana and sells through a regional distribution network and contract manufacturing partners. Consolidated H1 revenue (to 30 Sep 2025) was Rs. 690.90 lakhs, up materially versus the prior comparable period, but the company reported a consolidated loss before tax of Rs. 18.50 lakhs, reflecting margin pressure from higher purchases, other expenses and finance costs together with working capital stress and inventory movements. Standalone and consolidated financials diverge materially: standalone total revenue collapsed to Rs. 82.59 lakhs for H1 FY26 versus Rs. 435.80 lakhs a year earlier, while consolidated performance stayed larger due to subsidiary contribution; trade receivables remain elevated (consolidated Rs.1,298.15 lakhs), creating liquidity and credit risk for near-term operations. Strategic direction shows diversification: Fabino holds GMP and ISO 9001:2015 certifications, operates an Ayurvedic/herbal division, exports FMCG wellness products, owns brands ‘Fabino’ and ‘Keepshine’, and in 2023–24 expanded its corporate objects to include food, beverages and agriculture activities — a meaningful strategic pivot with potential to re-shape revenues.
Over the past 52 weeks, Fabino Enterprises Ltd has traded between a low of ₹13.01 and a high of ₹27.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Fabino Enterprises Ltd has a market capitalization of approximately 4.27. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Fabino Enterprises Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of -7.62 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 4.27 Cr, Fabino Enterprises Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Fabino Enterprises Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Fabino Enterprises Ltd is -7.62. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
The stock price was stated as ₹20.31 as of 23 Aug, 2026.
The offer opens on June 29, 2026 and closes on July 10, 2026.
Pharmaceuticals & Biotechnology
Pharmaceuticals
4 Cr
Low Risk
-7.6
39.5
—
1.2
27.00
13.01
Sales CAGR
Profit CAGR
ROE
ROCE